Amphastar Pharmaceuticals Inc

24 aug. 2026, 21:01 UTC

Amphastar Pharmaceuticals shares are lower in after-market hours, continuing a five-session decline. No specific news was identified to explain the price movement.

21 aug. 2026, 19:56 UTC

Amphastar Pharmaceuticals Inc shares are lower today, despite earlier fluctuations. No specific news has been identified to explain the price movement.

20 aug. 2026, 19:51 UTC

Amphastar Pharmaceuticals shares are higher, supported by a positive market environment and economic indicators showing strength in the broader economy.

19 aug. 2026, 19:36 UTC

Barclays raised its price target on Amphastar Pharmaceuticals to $23.00, contributing to positive sentiment as shares remain well above their 20-day moving average.

18 aug. 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc shares are higher today, reflecting market volatility amid rising U.S. Treasury yields and inflation concerns linked to geopolitical tensions.

17 aug. 2026, 19:16 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid routine market fluctuations and concerns over slowing growth following declines in U.S. retail sales and consumer sentiment.

14 aug. 2026, 20:01 UTC

Amphastar Pharmaceuticals is trading higher, rebounding from an early session low. The stock remains above its 20-day moving average despite no specific news.

12 aug. 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11 aug. 2026, 19:56 UTC

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10 aug. 2026, 19:36 UTC

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7 aug. 2026, 19:51 UTC

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6 aug. 2026, 23:02 UTC

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4 aug. 2026, 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 aug. 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31 iul. 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30 iul. 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29 iul. 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28 iul. 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24 iul. 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22 iul. 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21 iul. 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

20 iul. 2026, 19:56 UTC

Amphastar Pharmaceuticals is gaining modestly during Monday's session amid mixed market conditions and geopolitical tensions affecting oil prices and inflation concerns.